Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 13 2024
0mins
Source: NASDAQ.COM
Overview of Vident International Equity Strategy ETF (VIDI): Launched in 2013, VIDI is a smart beta ETF that aims to outperform the World ETFs segment by utilizing a principles-based selection strategy and balancing risk across developed and emerging markets, with an expense ratio of 0.61% and a 12-month dividend yield of 3.50%.
Comparison with Other ETFs: While VIDI has shown positive performance, investors may also consider lower-cost traditional market cap weighted ETFs like Vanguard Total International Stock ETF (VXUS) and Vanguard FTSE Developed Markets ETF (VEA), which have significantly lower expense ratios and larger asset bases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 239.400
Low
188.00
Averages
218.92
High
263.00
Current: 239.400
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UBS Upgrades Jazz Pharmaceuticals to Buy, Highlights Ziihera's Potential
- Rating Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy, primarily based on the commercial potential of Ziihera in biliary tract cancer treatment, indicating increasing market confidence in the drug's prospects.
- FDA Application Progress: Jazz's supplemental Biologics License Application has been accepted by the FDA, seeking to expand Ziihera's indication in gastroesophageal adenocarcinoma, with a decision expected on August 25, 2026, further enhancing investor expectations for the company's future.
- Sales Growth: Ziihera generated $13.3 million in revenue in Q1 2026, a significant increase from $9 million in Q4 2025, reflecting accelerated sales that have positively impacted the company's performance.
- Financial Forecast Revision: UBS analyst revised Jazz's revenue and EPS CAGR estimates for 2026-2030 to 10% and 11%, respectively, surpassing consensus estimates of 7% and 6%, demonstrating an optimistic outlook on the company's future growth.
See More
Latest Wall Street Ratings and Price Target Adjustments
- Micron Price Target Increase: Citigroup raised Micron Technology's price target from $425 to $840, anticipating a 40% increase in DRAM prices in Q2, which will significantly enhance its market competitiveness.
- Jazz Pharmaceuticals Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy and raised its price target from $188 to $307, driven by increased confidence in the commercial potential of its cancer drug Ziihera, which is expected to boost company performance.
- Nvidia Price Target Boost: HSBC raised Nvidia's price target from $295 to $325, expecting the company to exceed market expectations in its upcoming earnings report, further enhancing its profitability.
- Costco Price Target Increase: Oppenheimer raised Costco's price target from $1,100 to $1,160, believing that its defensive characteristics and superior value proposition will continue to drive market share growth, with potential catalysts for a special dividend or stock split.
See More
Jazz Pharmaceuticals to Participate in Investor Conferences
- Investor Conference Participation: Jazz Pharmaceuticals announced that its management will participate in several investor conferences, highlighting the company's commitment to investor communication aimed at boosting market confidence and attracting potential investors.
- Webcast Availability: Audio webcasts of the conferences will be available via the Investors section of Jazz Pharmaceuticals' website, ensuring that investors can access real-time updates on the company's latest developments, enhancing transparency and information sharing.
- Focus on Patient Needs: Jazz Pharmaceuticals is dedicated to developing life-changing medicines for rare diseases, emphasizing its innovative capabilities in areas with limited treatment options, further solidifying its leadership position in the biopharmaceutical industry.
- Global Business Presence: Headquartered in Dublin, Ireland, the company has research and development laboratories and manufacturing facilities in multiple countries, showcasing its global business strategy and commitment to serving patients worldwide.
See More
Foreign Healthcare Stocks Show Strong Quant Ratings
- Top Quant Ratings: Jazz Pharmaceuticals (JAZZ) leads with a 4.86 Quant score, showcasing its strong competitive position as one of the highest-rated specialty pharma companies globally, driven by a diversified neuroscience and oncology portfolio.
- Pipeline Excellence: AstraZeneca (AZN) follows closely with a 4.75 rating, reflecting the UK giant's exceptional pipeline execution and its status as one of the few mega-cap pharma companies currently favored by the Quant system.
- Focus on Specialty Drugs: Japanese pharma Astellas (ALPMY) and Swedish Orphan Biovitrum (SWOBY) round out the top four with scores of 4.64 and 4.63, respectively, highlighting the significance of specialty and orphan drug pipelines in the foreign healthcare sector's appeal.
- Market Disparity: While the top four stocks excel, Sandoz (SDZNY) and Galderma (GALDY) sit lower on the list with scores of 3.35, serving as a reminder that not all foreign healthcare stocks receive equal treatment from the Quant system, indicating a clear market disparity.
See More
Jazz Pharmaceuticals Reports Strong Q1 Performance
- Performance Growth: Jazz Pharmaceuticals delivered a strong Q1 performance, with broad-based growth across its commercial portfolio, indicating robust competitiveness in the market despite the lack of specific financial data.
- Commercial Portfolio Success: The positive performance across various business segments suggests a diverse product lineup and strong market demand, potentially laying the groundwork for sustained future growth.
- Market Reaction: Investors reacted positively to Jazz Pharmaceuticals' Q1 results, and while detailed data is lacking, the market sentiment appears optimistic regarding the company's future prospects, which may drive stock price appreciation.
- Strategic Implications: The strong quarterly performance not only enhances the company's position in the biopharmaceutical industry but may also attract more investor interest, thereby providing funding support for subsequent business expansion and R&D investments.
See More
Jazz Pharmaceuticals Reports Record Q1 2026 Earnings with $1.1 Billion Revenue
- Record Revenue: Jazz Pharmaceuticals achieved total revenues of $1.1 billion in Q1 2026, marking the highest in the company's history, primarily driven by the outstanding performance of Xywav, Epidiolex, Modeyso, and Zepzelca, indicating strong growth potential in the market.
- Ziihera Regulatory Progress: The FDA has accepted the sBLA for Ziihera and granted priority review, with an expected approval date of August 25, 2026, and management stated they are ready to launch immediately upon approval, enhancing the company's market position in gastric cancer.
- Xywav Sales Growth: Xywav's net product sales increased by 18% to $408 million, with approximately 425 new patients added and around 16,600 active patients, demonstrating strong demand and an expanding customer base for the product.
- Full-Year Financial Outlook: The company reaffirmed its total revenue guidance for 2026 at $4.25 billion to $4.5 billion, despite anticipating increased competition in the sleep business in the second half of the year, while maintaining an optimistic outlook on the growth potential of multiple products.
See More
UBS Upgrades Jazz Pharmaceuticals to Buy, Highlights Ziihera's Potential
- Rating Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy, primarily based on the commercial potential of Ziihera in biliary tract cancer treatment, indicating increasing market confidence in the drug's prospects.
- FDA Application Progress: Jazz's supplemental Biologics License Application has been accepted by the FDA, seeking to expand Ziihera's indication in gastroesophageal adenocarcinoma, with a decision expected on August 25, 2026, further enhancing investor expectations for the company's future.
- Sales Growth: Ziihera generated $13.3 million in revenue in Q1 2026, a significant increase from $9 million in Q4 2025, reflecting accelerated sales that have positively impacted the company's performance.
- Financial Forecast Revision: UBS analyst revised Jazz's revenue and EPS CAGR estimates for 2026-2030 to 10% and 11%, respectively, surpassing consensus estimates of 7% and 6%, demonstrating an optimistic outlook on the company's future growth.
See More
Latest Wall Street Ratings and Price Target Adjustments
- Micron Price Target Increase: Citigroup raised Micron Technology's price target from $425 to $840, anticipating a 40% increase in DRAM prices in Q2, which will significantly enhance its market competitiveness.
- Jazz Pharmaceuticals Upgrade: UBS upgraded Jazz Pharmaceuticals from Neutral to Buy and raised its price target from $188 to $307, driven by increased confidence in the commercial potential of its cancer drug Ziihera, which is expected to boost company performance.
- Nvidia Price Target Boost: HSBC raised Nvidia's price target from $295 to $325, expecting the company to exceed market expectations in its upcoming earnings report, further enhancing its profitability.
- Costco Price Target Increase: Oppenheimer raised Costco's price target from $1,100 to $1,160, believing that its defensive characteristics and superior value proposition will continue to drive market share growth, with potential catalysts for a special dividend or stock split.
See More
Jazz Pharmaceuticals to Participate in Investor Conferences
- Investor Conference Participation: Jazz Pharmaceuticals announced that its management will participate in several investor conferences, highlighting the company's commitment to investor communication aimed at boosting market confidence and attracting potential investors.
- Webcast Availability: Audio webcasts of the conferences will be available via the Investors section of Jazz Pharmaceuticals' website, ensuring that investors can access real-time updates on the company's latest developments, enhancing transparency and information sharing.
- Focus on Patient Needs: Jazz Pharmaceuticals is dedicated to developing life-changing medicines for rare diseases, emphasizing its innovative capabilities in areas with limited treatment options, further solidifying its leadership position in the biopharmaceutical industry.
- Global Business Presence: Headquartered in Dublin, Ireland, the company has research and development laboratories and manufacturing facilities in multiple countries, showcasing its global business strategy and commitment to serving patients worldwide.
See More
Foreign Healthcare Stocks Show Strong Quant Ratings
- Top Quant Ratings: Jazz Pharmaceuticals (JAZZ) leads with a 4.86 Quant score, showcasing its strong competitive position as one of the highest-rated specialty pharma companies globally, driven by a diversified neuroscience and oncology portfolio.
- Pipeline Excellence: AstraZeneca (AZN) follows closely with a 4.75 rating, reflecting the UK giant's exceptional pipeline execution and its status as one of the few mega-cap pharma companies currently favored by the Quant system.
- Focus on Specialty Drugs: Japanese pharma Astellas (ALPMY) and Swedish Orphan Biovitrum (SWOBY) round out the top four with scores of 4.64 and 4.63, respectively, highlighting the significance of specialty and orphan drug pipelines in the foreign healthcare sector's appeal.
- Market Disparity: While the top four stocks excel, Sandoz (SDZNY) and Galderma (GALDY) sit lower on the list with scores of 3.35, serving as a reminder that not all foreign healthcare stocks receive equal treatment from the Quant system, indicating a clear market disparity.
See More
Jazz Pharmaceuticals Reports Strong Q1 Performance
- Performance Growth: Jazz Pharmaceuticals delivered a strong Q1 performance, with broad-based growth across its commercial portfolio, indicating robust competitiveness in the market despite the lack of specific financial data.
- Commercial Portfolio Success: The positive performance across various business segments suggests a diverse product lineup and strong market demand, potentially laying the groundwork for sustained future growth.
- Market Reaction: Investors reacted positively to Jazz Pharmaceuticals' Q1 results, and while detailed data is lacking, the market sentiment appears optimistic regarding the company's future prospects, which may drive stock price appreciation.
- Strategic Implications: The strong quarterly performance not only enhances the company's position in the biopharmaceutical industry but may also attract more investor interest, thereby providing funding support for subsequent business expansion and R&D investments.
See More
Jazz Pharmaceuticals Reports Record Q1 2026 Earnings with $1.1 Billion Revenue
- Record Revenue: Jazz Pharmaceuticals achieved total revenues of $1.1 billion in Q1 2026, marking the highest in the company's history, primarily driven by the outstanding performance of Xywav, Epidiolex, Modeyso, and Zepzelca, indicating strong growth potential in the market.
- Ziihera Regulatory Progress: The FDA has accepted the sBLA for Ziihera and granted priority review, with an expected approval date of August 25, 2026, and management stated they are ready to launch immediately upon approval, enhancing the company's market position in gastric cancer.
- Xywav Sales Growth: Xywav's net product sales increased by 18% to $408 million, with approximately 425 new patients added and around 16,600 active patients, demonstrating strong demand and an expanding customer base for the product.
- Full-Year Financial Outlook: The company reaffirmed its total revenue guidance for 2026 at $4.25 billion to $4.5 billion, despite anticipating increased competition in the sleep business in the second half of the year, while maintaining an optimistic outlook on the growth potential of multiple products.
See More
